Sisu Pharma, Inc.

CHAPEL HILL, NC · Founded 2019 · CIK 0001817799 · Biotech · Private

Heat Shock Factor 1 (HSF1) degrader small molecules for oncology and neurodegenerative disease

sisupharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.7M
1 Form D · Jul 2020
75 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,699,998
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1781Altos Labs——
1782BIOMORPH TECHNOLOGIES LLC——
1783LIPO-IMMUNO TECH, LLC——
1784Sisu Pharma, Inc.—$1.7M
1785Function Therapeutics, Inc.——
1786SmartLife, Inc.—$225K
1787Evofem Biosciences, Inc.—$86M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Jiaoti HuangDirector · Executive Officer · Promoter
  • Sean O'BrienDirector · Executive Officer · Promoter
  • Michael Serrano-WuDirector
  • Dennis ThieleDirector · Executive Officer · Promoter

Patents

USPTO · 0 granted of 2
  • Compositions And Methods For The Treatment Of Cancerapplication
  • Methods For The Treatment Of Cancerapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.